You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 127 No. 11, November 1992 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  PAPERS PRESENTED AT THE 45TH ANNUAL CANCER SYMPOSIUM OF THE SOCIETY OF SURGICAL ONCOLOGY, NEW YORK, NY, MARCH 15-18, 1992
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Supplemental Dietary Glutamine on Methotrexate Concentrations in Tumors

V. Suzanne Klimberg, MD; Alex A. Pappas, MD; Emmanuel Nwokedi; Joseph C. Jensen, MD; J. Ralph Broadwater, MD; Nicholas P. Lang, MD; Kent C. Westbrook, MD

Arch Surg. 1992;127(11):1317-1320.


Abstract



• This study evaluated the effects of supplemental dietary glutamine (GLN) on methotrexate sodium concentrations in tumors and serum of sarcoma-bearing rats following the initiation of methotrexate. After randomization to a GLN diet (+GLN) or GLN-free diet (–GLN), tumor-bearing rats received 20 mg/kg of methotrexate sodium by intraperitoneal injection. The provision of supplemental GLN in the diet increased methotrexate concentrations in tumor tissues at 24 and 48 hours (38.0±0.20 nmol/g for the +GLN group vs 28.8±0.10 nmol/g for the –GLN group and 35.6±0.18 nmol/g for the +GLN group vs 32.5±0.16 nmol/g for the –GLN group, respectively). Arterial methotrexate levels were elevated only at 48 hours (0.147±0.007 µm/L for the +GLN group vs 0.120±0.006 µm/L for the –GLN group). Tumor morphometrics were not different between the groups but significantly greater tumor volume loss was seen even at 24 hours (–2.41±1.3 cm3 for the +GLN group vs –0.016±0.9 cm3 for the –GLN group). Tumor glutaminase activity was suppressed in both groups at 48 hours, but more so in the +GLN group (0.94 ±0.13 µmol/g per hour for the +GLN group vs 1.47±0.22 µmol/g per hour for the –GLN group). This study suggests that GLN may have therapeutic as well as nutritional benefit in oncology patients.

(Arch Surg. 1992;127:1317-1320)



Author Affiliations



From the Department of Surgery, University of Arkansas for Medical Sciences, Little Rock.


Footnotes



Accepted for publication July 25, 1992.

Presented at the 45th Annual Cancer Symposium of the Society of Surgical Oncology, New York, NY, March 16, 1992.

Reprint requests to Department of Surgery, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 725, Little Rock, AR 72205 (Dr Klimberg).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Oral Glutamine Protects against Acute Doxorubicin-Induced Cardiotoxicity of Tumor-Bearing Rats
Todorova et al.
J. Nutr. 2010;140:44-48.
ABSTRACT | FULL TEXT  

L-Glutamine Use in the Treatment and Prevention of Mucositis and Cachexia: A Naturopathic Perspective
Noe
Integr Cancer Ther 2009;8:409-415.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.